| scholarly article | Q13442814 |
| P50 | author | Sadia Saeed | Q56810515 |
| Lucia Altucci | Q57020535 | ||
| Hendrik Gerard Stunnenberg | Q85416865 | ||
| P2093 | author name string | Edo Vellenga | |
| Joost H A Martens | |||
| Femke Simmer | |||
| Amit Mandoli | |||
| Abhishek A Singh | |||
| Bart-Jan Wierenga | |||
| P2860 | cites work | Model-based analysis of ChIP-Seq (MACS) | Q21183902 |
| Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias | Q22009417 | ||
| Identification of novel functional TBP-binding sites and general factor repertoires | Q24295026 | ||
| PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia | Q24299511 | ||
| Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes | Q24338109 | ||
| The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein | Q24522515 | ||
| ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain | Q24548340 | ||
| ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification | Q24629886 | ||
| Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML | Q28118823 | ||
| The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus | Q28241824 | ||
| Core-binding factors in hematopoiesis and immune function | Q28262826 | ||
| The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells | Q28281239 | ||
| CBFbeta is critical for AML1-ETO and TEL-AML1 activity | Q30439864 | ||
| Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage | Q33385721 | ||
| AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets | Q33388188 | ||
| Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo | Q34000149 | ||
| The ETS-domain transcription factor family | Q34066415 | ||
| PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. | Q34099047 | ||
| E protein silencing by the leukemogenic AML1-ETO fusion protein | Q34343884 | ||
| The ETO (MTG8) gene family | Q35057262 | ||
| Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. | Q35134867 | ||
| Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia | Q35553360 | ||
| The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation | Q35650662 | ||
| Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells | Q35779705 | ||
| The Runx genes: lineage-specific oncogenes and tumor suppressors | Q35779743 | ||
| Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. | Q36166902 | ||
| Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets | Q36562726 | ||
| Cooperative binding of Ets-1 and core binding factor to DNA | Q36644903 | ||
| Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes | Q37115270 | ||
| Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation | Q37449132 | ||
| Acute myeloid leukemia: a central role for the ETS factor ERG. | Q37888001 | ||
| Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair | Q38347126 | ||
| Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. | Q39576827 | ||
| Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. | Q39606660 | ||
| Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. | Q39649034 | ||
| ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays | Q45113427 | ||
| Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity. | Q45945266 | ||
| Prognostically useful gene-expression profiles in acute myeloid leukemia. | Q51999490 | ||
| Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. | Q52187583 | ||
| Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. | Q52524249 | ||
| Promotion and maintenance of leukemia by ERG. | Q53268059 | ||
| Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. | Q53408223 | ||
| STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. | Q53540863 | ||
| The Biology of Hematopoietic Stem Cells | Q58043095 | ||
| High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study | Q59315411 | ||
| The role of CBFbeta in AML1-ETO's activity | Q84585440 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| leukemia | Q29496 | ||
| P304 | page(s) | 4038-4048 | |
| P577 | publication date | 2012-09-14 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia | |
| P478 | volume | 120 |
| Q48721287 | A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program |
| Q27678844 | A stable transcription factor complex nucleated by oligomeric AML1–ETO controls leukaemogenesis |
| Q39058012 | AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis |
| Q33753763 | ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. |
| Q38172135 | Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells |
| Q37661800 | BloodChIP: a database of comparative genome-wide transcription factor binding profiles in human blood cells |
| Q42444092 | CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. |
| Q55177661 | Cancer epigenetics: Moving forward. |
| Q41089332 | Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature. |
| Q35018112 | Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia |
| Q42602670 | Developmental-stage-dependent transcriptional response to leukaemic oncogene expression. |
| Q37416999 | Differential involvement of E2A-corepressor interactions in distinct leukemogenic pathways. |
| Q47681816 | Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells |
| Q35568467 | Flow-induced protein kinase A-CREB pathway acts via BMP signaling to promote HSC emergence |
| Q52718189 | GFI1 is required for RUNX1/ETO positive acute myeloid leukemia. |
| Q35944651 | Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells |
| Q35619449 | Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells |
| Q47127883 | Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation |
| Q35806108 | Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal |
| Q38683676 | Immune evasion by oncogenic proteins of acute myeloid leukemia |
| Q26781526 | Interplay between Transcription Factors and the Epigenome: Insight from the Role of RUNX1 in Leukemia |
| Q36199628 | JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors |
| Q45847205 | LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype |
| Q35575250 | Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis |
| Q39004166 | MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia |
| Q41996826 | Major transcriptional changes observed in the Fulani, an ethnic group less susceptible to malaria |
| Q52718151 | Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. |
| Q37679748 | New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins. |
| Q60044760 | Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas |
| Q38310344 | Pontin is a critical regulator for AML1-ETO-induced leukemia |
| Q26781101 | Potential Gene Interactions in the Cell Cycles of Gametes, Zygotes, Embryonic Stem Cells and the Development of Cancer |
| Q90162763 | RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction |
| Q51097627 | RUNX1-ETO Leukemia |
| Q33759034 | RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML. |
| Q38904253 | Runx1 Structure and Function in Blood Cell Development |
| Q27679276 | Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited |
| Q64911185 | Subtype-specific regulatory network rewiring in acute myeloid leukemia. |
| Q55714869 | The Co-operation of RUNX1 with LDB1, CDK9 and BRD4 Drives Transcription Factor Complex Relocation During Haematopoietic Specification. |
| Q57293716 | The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation |
| Q38370113 | The RUNX1-PU.1 axis in the control of hematopoiesis. |
| Q92205729 | The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model |
| Q38218534 | The ets transcription factor Fli-1 in development, cancer and disease |
| Q38856290 | The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia. |
| Q55322172 | The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition. |
| Q51188023 | The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells. |
| Q27005940 | Transcriptional network control of normal and leukaemic haematopoiesis |
| Q92337654 | Transcriptional networks in acute myeloid leukemia |
Search more.